Cerevel Therapeutics Holdings, Inc.
CEREDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001805387
Cerevel Therapeutics Holdings, Inc. was delisted in 2024; its insiders filed their last Form 4 on Aug 5, 2024; 231 institutions reported holding it in 13F filings for Q2 2024, worth $6.45B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 231
- Q2 2024, +23 vs. previous quarter
- 13F value
- $6.45B
- Reported value at the end of Q2 2024
- Superinvestors holding
- 1
- At the end of Q2 2024
Superinvestors holding CERE, Q2 2024
1 superinvestor reports holding Cerevel Therapeutics Holdings, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
2.0%
Cerevel Therapeutics Holdings, Inc.'s share of the portfolio
- Shares
- 2,151,641
- Value
- $88.0M
Latest insider trades
Open-market purchases and sales by Cerevel Therapeutics Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Coles N AnthonyDirector | SSale | −25.0K | $41.18 | −$1.03M | −49.1%25.9K after | 10b5-1 |
| Jun 5, 2024 (view filing) | Jun 3 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $40.61 | −$2.03M | −76.2%15.6K after | 10b5-1 |
| May 14, 2024 (view filing) | May 10 | 4 days | Coles N AnthonyDirector | SSale | −50.0K | $42.10 | −$2.10M | −76.2%15.6K after | 10b5-1 |
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $42.33 | −$2.12M | −76.2%15.6K after | 10b5-1 |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $41.01 | −$2.05M | −76.2%15.6K after | 10b5-1 |
| Mar 4, 2024 (view filing) | Feb 29 | 4 days | Coles N AnthonyDirector | SSale | −50.0K | $41.16 | −$2.06M | −76.2%15.6K after | 10b5-1 |
| Feb 8, 2024 (view filing) | Feb 7 | 1 day | Renger JohnChief Scientific Officer | SSale | −2.16K | $41.54 | −$89.8K | −25.3%6.37K after | |
| Feb 8, 2024 (view filing) | Feb 7 | 1 day | Coles N AnthonyDirector | SSale | −2.51K | $41.54 | −$104.1K | −13.8%15.6K after | |
| Jan 4, 2024 (view filing) | Jan 2 | 2 days | Coles N AnthonyDirector | SSale | −50.0K | $42.24 | −$2.11M | −94.9%2.70K after | 10b5-1 |
| Dec 28, 2023 (view filing) | Dec 26 | 2 days | Sanchez RamiroChief Medical Officer | SSale | −10.0K | $42.47 | −$424.7K | −40.5%14.7K after | 10b5-1 |
Top 10 13F holders, Q2 2024
The largest institutional positions in Cerevel Therapeutics Holdings, Inc. at the end of Q2 2024; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Investors LLC | 65,679,781 | $2.69B | 57.02% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 10,794,876 | $441.4M | 10.65% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 7,539,547 | $308.3M | 4.11% | −16,008−0.2% | Reduced |
| Vanguard Group Inc | 7,154,343 | $292.5M | 0.01% | −309,568−4.1% | Reduced |
| BlackRock Inc. | 3,560,931 | $145.6M | 0.00% | −1,887,689−34.6% | Reduced |
| FIL Ltd | 3,252,000 | $133.0M | 0.13% | +3,000+0.1% | Added |
| State Street Corp | 3,109,886 | $127.2M | 0.01% | −418,584−11.9% | Reduced |
| Alpine Associates Management Inc. | 2,353,694 | $96.2M | 4.63% | +12,300+0.5% | Added |
| Norges Bank | 2,335,746 | $95.5M | 0.01% | +1,610,692+222.1% | Added |
| Paradigm Biocapital Advisors LP | 2,330,508 | $95.3M | 3.65% | 00.0% | Unchanged |